Priority Review for Roche's MS candidate

The Genentech Inc. unit of Roche (SIX:ROG;

Read the full 77 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE